Mylan announced the launch of Memantine HCl Tablets, the generic version of ActavisNamenda.

Namenda is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. It is thought to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.

RELATED: Why Higher BP May Protect Against Alzheimer’s Risk

Memantine HCl Tablets are available in 5mg and 10mg strengths.

For more information call (800) RX-MYLAN or visit